Citation only
via OpenAlex
Ranibizumab for age-related macular degeneration
Dilsher S. Dhoot, Peter K. Kaiser
Expert Opinion on Biological Therapy · 2012 · ▲ 54 citations
Abstract
INTRODUCTION: Age-related macular degeneration (AMD) is the leading cause of blindness in patients over 50 years in the developed world. The wet form of AMD is responsible for the majority of severe vision loss. VEGF-A is a key component in the development of wet AMD. Ranibizumab is an anti-VEGF agent that has established itself as the gold standard in the treatment of neovascular AMD. Herein, we review the pharmacology, pharmacokinetics, efficacy and safety of ranibizumab. AREAS COVERED: Since its approval in 2006, ranibizumab has revolutionized the treatment of wet AMD. In two pivotal Phase III trials, MARINA and ANCHOR, ranibizumab (0.5 mg) prevented moderate visual loss in 90 and 96% of patients, respectively, and improved vision by 15 letters or more in 33 and 40% of patients, respectively. Fixed monthly dosing regimens were compared with quarterly dosing regimens in PIER and EXCITE studies and support the superiority of fixed monthly dosing. The CATT trial revealed that bevacizumab was not inferior to ranibizumab when dosed monthly. As-needed treatment regimens of ranibizumab were also found to be non-inferior to monthly ranibizumab after 1 year of follow-up. EXPERT OPINION: Ranibizumab has positively altered the treatment of wet AMD and offers hope for millions of patients.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1517/14712598.2012.660523
- Canonical
- link ↗
- Fetched
- 2026-10-19 MST
Cite this
APA
Dhoot, D.S., & Kaiser, P.K. (2012). Ranibizumab for age-related macular degeneration. <em>Expert Opinion on Biological Therapy</em>. https://doi.org/10.1517/14712598.2012.660523
Vancouver
Dhoot DS, Kaiser PK. Ranibizumab for age-related macular degeneration. Expert Opinion on Biological Therapy. 2012. doi:10.1517/14712598.2012.660523.
BibTeX
@article{dilsher2012Ranibi,
title = {Ranibizumab for age-related macular degeneration},
author = {Dilsher S. Dhoot and Peter K. Kaiser},
journal = {Expert Opinion on Biological Therapy},
year = {2012},
doi = {10.1517/14712598.2012.660523},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
St. Erik Eye Hospital 2006
Open access · US-GOV
A Prospective, Randomized, Double-masked, Controlled Study on Intravitreal Bevacizumab (Avastin) Versus Verteporfin (Visudyne) Photodynamic Therapy (PDT) for Patients With Neovascular Age-related Macular Degeneration (AMD)
Developments in ophthalmology 2015
Citation only
Neovascular Age-Related Macular Degeneration
NeoVista 2008
Open access · US-GOV
A Study of the NeoVista Ophthalmic System for the Treatment of Subfoveal Choroidal Neovascularization Associated With Wet Age-Related Macular Degeneration in Patients That Require Persistent Anti-VEGF Therapy
Novartis Pharmaceuticals 2014
Open access · US-GOV
A Phase IV, Prospective, Open-label, Uncontrolled, European Study in Patients With Neovascular Age-related Macular Degeneration (nAMD), Evaluating the Efficacy and Safety of Switching From Intravitreal Aflibercept to Ranibizumab 0.5mg.
Novartis 2005
Open access · US-GOV
A Randomized, Double-Masked, Multicenter, Phase I/II Study of the Safety of PTK787 Administered to Patients With Predominantly Classic , Minimally Classic or Occult With no Classic Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
Control Delivery Systems 2001
Open access · US-GOV